3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Thyroid Cancer, Papillary
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
pembrolizumab
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Fluorodeoxyglucose F18
2
FAPI-46
2
tivozanib
1
taxane
1
liposomal doxorubicin
1
fludarabine
1
entrectinib
1
atezolizumab
1
alectinib
1
aldesleukin
1
Vinorelbine
1
RRx-001
1
Quality of Life
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Paclitaxel
1
PM 01183
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Gemcitabine
1
Etoposide
1
Drug Therapy
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
entrectinib
×
Gynecologic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA